NIKKEI 225
39,074.32 +457.22 (+1.18%) HANG SENG
18,930.02 -265.58 (-1.38%) CRUDE OIL
77.10 -0.47 (-0.61%) GOLD FUTURES
2,374.30 -18.60 (-0.78%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,542.11 -310.59 (-0.57%)
GILD Jan 2025 62.500 put
| Previous close | 2.9000 |
| Open | 2.7300 |
| Bid | 2.4300 |
| Ask | 2.7600 |
| Strike | 62.50 |
| Expiry date | 2025-01-17 |
| Day's range | 2.7300 - 2.8300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.2k |
Business WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
ZacksHere is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
BenzingaGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study. The ASSURE study is an open-label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical trials of seladelpar. The study is currently enrolling up to 500 people. Also Read: Gilead’s Aggressive Push Beyond HIV Treatments
